Myc matters in HIV-associated lymphoma.

In of present the results of a randomized phase 2 trial that tested the addition of the oral histone deacetylase (HDAC) inhibitor vorinostat to standard rituximab plus etoposide, prednisone, vincristine, cyclo-phosphamide, and doxorubicin (R-EPOCH) for patients with HIV-associated diffuse large B-cell lymphoma (DLBCL). Although it was solidly based on pre-clinical data supporting the concept that an HDAC inhibitor would add ef fi cacy in tumors that often harbor Epstein-Barr virus in the setting of HIV infection, it did not translate into a better result in the clinic, at least with this HDAC inhibitor combined with the R-EPOCH backbone. The complete remission (CR) rates with R-EPOCH (74%) vs R-EPOCH with vorinostat (68%) ( P 5 .72) and the overall survival (OS) and event-free survival (EFS) rates were similar between arms.

[1]  E. Cesarman,et al.  Impact of Myc in HIV-associated Non-Hodgkin Lymphomas Treated with EPOCH, and Outcomes with Vorinostat (AMC075 Trial). , 2020, Blood.

[2]  T. Habermann,et al.  High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? , 2020, Blood Cancer Journal.

[3]  D. Scott,et al.  ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP , 2019, Hematological Oncology.

[4]  L. Staudt,et al.  Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Cerhan,et al.  Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements , 2018, Haematologica.

[6]  A. Rosenwald,et al.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.

[7]  J. Cerhan,et al.  Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gascoyne,et al.  Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era , 2018, Blood Cancer Journal.

[9]  M. Oestergaard,et al.  PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY , 2017 .

[10]  T. Habermann,et al.  The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma , 2011, Leukemia.